公开(公告)号：US20210145978A1

公开(公告)日：2021-05-20

申请号：US17105402

申请日：2020-11-25

Applicant: AbbVie Inc.

Inventor： Shweta Singh ,  Jennifer Hope Richardson ,  Laura Patterson Serwer ,  Jonathan Alexander Terret ,  Susan E. Morgan-Lappe ,  Tracy Henriques ,  Sherry L. Ralston ,  Marvin Robert Leanna ,  Ilari Badagnani ,  Sahana Bose

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US09469689B2

公开(公告)日：2016-10-18

申请号：US14798849

申请日：2015-07-14

Applicant: AbbVie Inc.

Inventor： Ming-Jiu Chen ,  Chung-Ming Hsieh ,  Jijie Gu ,  Susan E. Morgan-Lappe ,  Yingchun Li

IPC: C07K16/00 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

公开(公告)号：US20160319026A1

公开(公告)日：2016-11-03

申请号：US15091468

申请日：2016-04-05

Applicant: AbbVie Inc.

Inventor： Tariq Ghayur ,  Junjian Liu ,  Gillian A. Kingsbury ,  Edward B. Reilly ,  Susan E. Morgan-Lappe ,  Jijie Gu

IPC: C07K16/28 ,  G01N33/74 ,  A61K39/395 ,  A61K47/48 ,  A61K45/06

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/74 ,  G01N2333/71 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

公开(公告)号：US20150104452A1

公开(公告)日：2015-04-16

申请号：US14301305

申请日：2014-06-10

Applicant: AbbVie Inc.

Inventor： Tariq Ghayur ,  Edward B. Reilly ,  Andrew Phillips ,  Randy L. Bell ,  Yingchun Li ,  Hua Ying ,  Susan E. Morgan-Lappe ,  Gillian A. Kingsbury ,  Jieyi Wang ,  Suzanne M. Norvell ,  Junjian Liu

IPC: C07K16/46 ,  A61K45/06 ,  G01N33/68 ,  C07K16/28 ,  G01N33/74 ,  A61K39/395 ,  C07K16/22

CPC classification number: C07K16/468 ,  A61K39/39533 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  G01N33/6872 ,  G01N33/74 ,  G01N2333/515 ,  G01N2333/705 ,  Y02A50/386 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/58 ,  Y10S435/81

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.